NCT06477484 Blood Biomarkers for Screening of Alzheimer's Disease
| NCT ID | NCT06477484 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-06-18 |
| Primary Completion | 2026-03-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-06-18 with a primary completion date of 2026-03-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 50 years; * AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects; * Signed informed consent form. Exclusion Criteria: * The presence of other disorders that can cause cognitive impairment; * Unable to cooperate with the completion of cognitive assessment; * Refusal to draw blood.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06477484 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06477484 currently recruiting?
Yes, NCT06477484 is actively recruiting participants. Contact the research team at chenzizm@126.com for enrollment information.
Where is the NCT06477484 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06477484 clinical trial?
NCT06477484 is sponsored by Peking University First Hospital. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.